Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2010 - 2026)

Regeneron Pharmaceuticals' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $3.0 billion for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 20.53% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $3.0 billion (up 20.53% YoY), while the FY2025 annual figure was $2.9 billion, up 13.82% from the prior year.
• Accumulated Expenses for Q2 2026 stood at $3.0 billion, up from $2.7 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $3.0 billion in Q3 2025, with the low at $1.8 billion in Q3 2022.
• The 5-year median for Accumulated Expenses is $2.4 billion (2024), against an average of $2.4 billion.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses retreated 12.84% in 2022, then soared 47.22% in 2023.
• Regeneron Pharmaceuticals' Accumulated Expenses stood at $2.1 billion in 2022, then increased by 13.68% to $2.4 billion in 2023, then advanced by 7.18% to $2.5 billion in 2024, then gained by 13.82% to $2.9 billion in 2025, then grew by 3.13% to $3.0 billion in 2026.
• Business Quant data shows REGN's Accumulated Expenses at $3.0 billion in Q2 2026, $2.7 billion in Q1 2026, and $2.9 billion in Q4 2025.